S&P 500   3,901.36
DOW   31,261.90
QQQ   288.68
S&P 500   3,901.36
DOW   31,261.90
QQQ   288.68
S&P 500   3,901.36
DOW   31,261.90
QQQ   288.68
S&P 500   3,901.36
DOW   31,261.90
QQQ   288.68

Takeda Pharmaceutical (TAK) Stock Forecast, Price & News

+0.14 (+0.96%)
(As of 05/20/2022 07:00 PM ET)
Today's Range
50-Day Range
52-Week Range
4.16 million shs
Average Volume
2.82 million shs
Market Capitalization
$46.58 billion
P/E Ratio
Dividend Yield
30 days | 90 days | 365 days | Advanced Chart
Receive TAK News and Ratings via Email

Sign-up to receive the latest news and ratings for Takeda Pharmaceutical and its competitors with MarketBeat's FREE daily newsletter.

Takeda Pharmaceutical logo

About Takeda Pharmaceutical

Takeda Pharmaceutical Company Limited engages in the research, development, manufacturing, marketing, and out-licensing of pharmaceutical products worldwide. It offers pharmaceutical products in the areas of gastroenterology; oncology; neuroscience; and rare diseases, such as rare metabolic and hematology, and heredity angioedema, as well as plasma-derived therapies and vaccines. The company provides its products under the Entyvio, Gattex/Revestive, Alofisel, Natpara, Adynovate/Adynovi, Takhzyro, Elaprase, Vpriv, Gammagard Liquid/Kiovig, Hyqvia, Cuvitru, Albumin/Flexbumin, Ninlaro, and Alunbrig brands. Takeda Pharmaceutical Company has licensing agreements with Denali Therapeutics and Wave Life Sciences Ltd; collaboration agreements with Neurocrine Biosciences, Inc. and Rani Therapeutics LLC; license and research agreements with The University of Texas MD Anderson Cancer Center, Poseida Therapeutics, Inc., and Arrowhead Pharmaceuticals Inc.; research collaboration agreements with Arrowhead Pharmaceuticals Inc. and Ovid Therapeutics Inc.; and collaboration with Evox Therapeutics Ltd., as well as a licensing agreement with ProThera Biologics Inc. It also has strategic alliances with Egle Therapeutics SAS; Evotec SE; Neurocrine Biosciences, Inc.; Carmine Therapeutics; HemoShear Therapeutics, LLC; KSQ Therapeutics; and Anima Biotech. Takeda Pharmaceutical Company Limited was founded in 1781 and is headquartered in Tokyo, Japan.


See More Headlines

Industry, Sector and Symbol

Pharmaceutical preparations
Year Founded

Sales & Book Value

Annual Sales
$31.79 billion
Cash Flow
$3.54 per share
Book Value
$15.98 per share


Net Income
$2.05 billion
Pretax Margin




Outstanding Shares
Free Float
Market Cap
$46.58 billion

Company Calendar

Next Earnings (Estimated)
Fiscal Year End

Social Links


Overall MarketRank

1.20 out of 5 stars

Medical Sector

1180th out of 1,416 stocks

Pharmaceutical Preparations Industry

578th out of 677 stocks

Analyst Opinion: 0.0Community Rank: 3.7Dividend Strength: 1.7Insider Behavior: 0.0Valuation: 0.6 5 -4 -3 -2 -1 -

Takeda Pharmaceutical (NYSE:TAK) Frequently Asked Questions

Is Takeda Pharmaceutical a buy right now?

3 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Takeda Pharmaceutical in the last year. There are currently 2 hold ratings and 1 buy rating for the stock. The consensus among Wall Street analysts is that investors should "hold" Takeda Pharmaceutical stock. A hold rating indicates that analysts believe investors should maintain any existing positions they have in TAK, but not buy additional shares or sell existing shares.
View analyst ratings for Takeda Pharmaceutical
or view top-rated stocks.

Are investors shorting Takeda Pharmaceutical?

Takeda Pharmaceutical saw a increase in short interest in April. As of April 15th, there was short interest totaling 5,910,000 shares, an increase of 32.8% from the March 31st total of 4,450,000 shares. Based on an average daily volume of 2,580,000 shares, the short-interest ratio is currently 2.3 days. Approximately 0.2% of the company's shares are short sold.
View Takeda Pharmaceutical's Short Interest

When is Takeda Pharmaceutical's next earnings date?

Takeda Pharmaceutical is scheduled to release its next quarterly earnings announcement on Friday, July 29th 2022.
View our earnings forecast for Takeda Pharmaceutical

Is Takeda Pharmaceutical a good dividend stock?

Takeda Pharmaceutical pays an annual dividend of $0.66 per share and currently has a dividend yield of 4.48%. TAK has a dividend yield higher than 75% of all dividend-paying stocks, making it a leading dividend payer. The dividend payout ratio of Takeda Pharmaceutical is 77.65%. Payout ratios above 75% are not desirable because they may not be sustainable.

What guidance has Takeda Pharmaceutical issued on next quarter's earnings?

Takeda Pharmaceutical issued an update on its FY 2022 earnings guidance on Wednesday, May, 18th. The company provided EPS guidance of $3.99-$3.99 for the period. The company issued revenue guidance of $30.39 billion-$30.39 billion.

Who are Takeda Pharmaceutical's key executives?
Takeda Pharmaceutical's management team includes the following people:
  • Mr. Christophe Weber, Pres, CEO & Representative Director (Age 56, Pay $11.45M)
  • Mr. Constantine Saroukos, CFO & Representative Director (Age 51, Pay $4.13M)
  • Mr. Yasuhiko Yamanaka, Advisor (Age 66, Pay $290.97k)
  • Dr. Andrew S. Plump, Pres of R&D and Representative Director (Age 57, Pay $5.89M)
  • Dr. Seigo Izumo, Chair of Management Board
  • Mr. Haruhiko Hirate, Member of Management Board (Age 65)
  • Salvatore Alesci, Member of Management Board and Head of R&D Global Science & Biomedical Policy
  • Norimasa Takeda, Chief Accounting Officer & Corp. Controller
  • Mr. Iwaaki Taniguchi, Sr. VP of Corp. Fin. & Controlling Department
  • Mr. Gabriele Ricci, Chief Data & Technology Officer
What other stocks do shareholders of Takeda Pharmaceutical own?

Based on aggregate information from My MarketBeat watchlists, some companies that other Takeda Pharmaceutical investors own include Cisco Systems (CSCO), Johnson & Johnson (JNJ), Alibaba Group (BABA), Pfizer (PFE), Verizon Communications (VZ), AbbVie (ABBV), CVS Health (CVS), Gilead Sciences (GILD), AT&T (T) and Abbott Laboratories (ABT).

What is Takeda Pharmaceutical's stock symbol?

Takeda Pharmaceutical trades on the New York Stock Exchange (NYSE) under the ticker symbol "TAK."

Who are Takeda Pharmaceutical's major shareholders?

Takeda Pharmaceutical's stock is owned by many different retail and institutional investors. Top institutional shareholders include Mondrian Investment Partners LTD (0.14%), Goldman Sachs Group Inc. (0.13%), BlackRock Inc. (0.10%), Northern Trust Corp (0.07%), Brandes Investment Partners LP (0.07%) and Renaissance Technologies LLC (0.06%).

Which major investors are selling Takeda Pharmaceutical stock?

TAK stock was sold by a variety of institutional investors in the last quarter, including Citigroup Inc., UBS Group AG, Vanguard Group Inc., BNP Paribas Arbitrage SA, Northern Trust Corp, First Trust Advisors LP, Sei Investments Co., and Sawtooth Solutions LLC.

Which major investors are buying Takeda Pharmaceutical stock?

TAK stock was bought by a variety of institutional investors in the last quarter, including BlackRock Inc., Goldman Sachs Group Inc., Brandes Investment Partners LP, Renaissance Technologies LLC, Mondrian Investment Partners LTD, Clean Yield Group, Natixis Advisors L.P., and Arrowstreet Capital Limited Partnership.

How do I buy shares of Takeda Pharmaceutical?

Shares of TAK can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.
Compare Top Brokerages Here.

What is Takeda Pharmaceutical's stock price today?

One share of TAK stock can currently be purchased for approximately $14.72.

How much money does Takeda Pharmaceutical make?

Takeda Pharmaceutical has a market capitalization of $46.58 billion and generates $31.79 billion in revenue each year. The company earns $2.05 billion in net income (profit) each year or $0.849990 on an earnings per share basis.

How many employees does Takeda Pharmaceutical have?

Takeda Pharmaceutical employs 47,000 workers across the globe.

Does Takeda Pharmaceutical have any subsidiaries?

The following companies are subsidiares of Takeda Pharmaceutical: ARIAD Pharmaceuticals, Baxalta Manufacturing S.à r.l., IDM Pharma Inc., Intellikine, Inviragen, LigoCyte Pharmaceuticals, Meritage Pharma Inc., Millennium Pharmaceuticals, Millennium Pharmaceuticals Inc., Nihon Pharmaceutical Co. Ltd., Nycomed Pharma, PvP Biologics, Shire, Shire ViroPharma LLC, Takeda (China) Holdings Co. Ltd., Takeda AS, Takeda Austria GmbH, Takeda Bio Development Center, Takeda California Inc., Takeda Consumer Healthcare Company Limited, Takeda Development Center Americas Inc., Takeda Development Center Asia Pte. Ltd., Takeda Development Centre Europe Ltd., Takeda Distribuidora Ltda., Takeda France S.A.S., Takeda GmbH, Takeda Ireland Limited, Takeda Italia S.p.A., Takeda Pharma A/S, Takeda Pharmaceutical (China) Company Limited, Takeda Pharmaceuticals International AG, Takeda Pharmaceuticals Korea Co. Ltd., Takeda Pharmaceuticals Limited Liability Company, Takeda Pharmaceuticals U.S.A. Inc., Takeda UK Limited, Takeda Vaccines Inc., Takeda Vaccines Pte. Ltd., and TiGenix.

When was Takeda Pharmaceutical founded?

Takeda Pharmaceutical was founded in 1781.

What is Takeda Pharmaceutical's official website?

The official website for Takeda Pharmaceutical is www.takeda.com.

How can I contact Takeda Pharmaceutical?

Takeda Pharmaceutical's mailing address is 1-1 NIHONBASHI-HONCHO 2-CHOME CHUO-KU, TOKYO M0, 103-8668. The company can be reached via phone at (166) 204-2111 or via fax at 813-3278-2268.

This page was last updated on 5/23/2022 by MarketBeat.com Staff


Premium Research Tools

MarketBeat All Access subscribers can access stock screeners, the Idea Engine, data export tools, research reports, and other premium tools.

Discover All Access

Market Data and Calendars

Looking for new stock ideas? Want to see which stocks are moving? View our full suite of financial calendars and market data tables, all for free.

View Market Data

Investing Education and Resources

Receive a free world-class investing education from MarketBeat. Learn about financial terms, types of investments, trading strategies and more.

Financial Terms
Details Here
MarketBeat - Stock Market News and Research Tools logo

MarketBeat empowers individual investors to make better trading decisions by providing real-time financial data and objective market analysis. Whether you’re looking for analyst ratings, corporate buybacks, dividends, earnings, economic reports, financials, insider trades, IPOs, SEC filings or stock splits, MarketBeat has the objective information you need to analyze any stock. Learn more about MarketBeat.

MarketBeat is accredited by the Better Business Bureau MarketBeat is rated as Great on TrustPilot

© American Consumer News, LLC dba MarketBeat® 2010-2022. All rights reserved.
326 E 8th St #105, Sioux Falls, SD 57103 | U.S. Based Support Team at [email protected] | (844) 978-6257
MarketBeat does not provide personalized financial advice and does not issue recommendations or offers to buy stock or sell any security.

Our Accessibility Statement | Terms of Service | Do Not Sell My Information | RSS Feeds

© 2022 Market data provided is at least 10-minutes delayed and hosted by Barchart Solutions. Information is provided 'as-is' and solely for informational purposes, not for trading purposes or advice, and is delayed. To see all exchange delays and terms of use please see disclaimer. Fundamental company data provided by Zacks Investment Research.